CDH6 and hereditary clear cell renal cell carcinoma: HKT288, a first-generation anti-CDH6 ADC with a microtubule-targeting DM4 payload, has shown durable preclinical activity in 40% of patient-derived xenograft (PDX) models, especially those derived from ovarian cancer and renal cell carcinoma (Bialucha et al., 2017).